With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ:MRSN) with a Buy rating and a price target of $12. The analyst says the…
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Mersana Therapeutics Inc (NASDAQ:MRSN) signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany’s Merck KGaA (OTC:MKGAF) (OTC:MKKGY). Mersana would…
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Recap: Mersana Therapeutics Q3 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Mersana Therapeutics posted an EPS of $-0.61.
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers
Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…
Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).
Mersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Amphastar’s (NASDAQ:AMPH) New Drug Application (ND”) for Epinephrine injection…